Neurofibromatosis Treatment Global Market Report 2025
상품코드:1825472
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신경섬유종증 치료 시장의 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 13.1%로 242억 5,000만 달러로 성장할 전망입니다. 예측기간의 성장은 연구개발과 의약품 개발, 원격의료와 원격 모니터링, 환자 교육과 지원, 환급 정책에 기인할 것으로 예상됩니다. 예측기간의 주요 동향으로는 시력 회복 서비스, 공동 케어 모델, 데이터 분석 및 AI, 시신경 인공 기관 및 임플란트 등이 있습니다.
향후 5년간의 예측 성장률 13.1%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 스위스나 영국에서 수입되는 미토겐 활성화 단백질 키나아제(MEK) 억제제나 종양 억제 유전자 치료제의 비용을 상승시키고, 종양 관리를 손상시킬 가능성이나 신경섬유종증(NF) 환자의 전문 약국 비용을 상승시킴으로써 미국의 희귀질환 의료를 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.
건강 관리 지출 증가는 신경섬유종증 치료 시장의 확대를 촉진할 것으로 예측됩니다. 건강 관리 지출에는 의료, 예방 조치, 공중 보건 활동, 재활, 지역 보건 활동, 건강 조사와 관련된 모든 비용이 포함됩니다. 건강 관리 지출은 수술, 생검, MRI, CT 스캔 등의 영상검사 등 다양한 의료 처리를 수반하는 신경섬유종증 치료를 진행하는데 중요한 역할을 하고 있습니다. 또한, 건강 관리 지출은 일반 의료 및 신경섬유종증 치료와 같은 서비스를 지원합니다. 예를 들어, 2024년 5월 영국의 정부기관 Office for National Statistics는 2022년부터 2023년까지 총 건강 관리 지출이 5.6% 증가했다고 보고했습니다. 따라서 의료비 증가는 신경섬유종증 치료 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 신경섬유종증 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 신경섬유종증 치료 시장 : 성장률 분석
세계의 신경섬유종증 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 신경섬유종증 치료 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 신경섬유종증 치료 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 신경섬유종증 치료 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
신경섬유종증 1형(NF1)
신경섬유종증 2형(NF2)
신경초종
세계의 신경섬유종증 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
약
수술
방사선치료
기타 치료법
세계의 신경섬유종증 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원
클리닉
기타 최종 사용자
세계의 신경섬유종증 치료 시장 : 세분화 신경섬유종증 1(NF1)(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
외과적 개입
증상 관리를 위한 약물요법
유전 상담
세계의 신경섬유종증 치료 시장 : 세분화 신경섬유종증 2(NF2)(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
외과적 개입
방사선치료
증상 관리를 위한 약물요법
세계의 신경섬유종증 치료 시장 : 세분화 신경초종(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
외과적 개입
통증 관리 요법
유전 상담
제7장 지역별/국가별 분석
세계의 신경섬유종증 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 신경섬유종증 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
신경섬유종증 치료 시장 : 경쟁 구도
신경섬유종증 치료 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca plc
GSK PLC
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Gilead Sciences Inc.
Amgen Inc.
Vertex Pharmaceuticals Inc.
Dr. Reddy's Laboratories
BioMarin Pharmaceutical
Allergan
BeiGene Ltd.
BioXcel Therapeutics Inc.
Blueprint Medicines Corp.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
신경섬유종증 치료 시장(2029년) : 새로운 기회를 제공하는 국가
신경섬유종증 치료 시장(2029년) : 새로운 기회를 제공하는 부문
신경섬유종증 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Neurofibromatosis treatment involves addressing a genetic disorder that causes tumors to develop on nerve tissue, which can occur anywhere in the body, including the brain, spinal cord, and peripheral nerves. The treatment aims to manage symptoms, slow disease progression, and prevent complications associated with the condition.
Neurofibromatosis treatment encompasses approaches tailored for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis. Neurofibromatosis type 1 (NF1) is a hereditary disorder characterized by the development of tumors on nerves throughout the body. Various treatment modalities such as medications, surgical interventions, radiation therapy, and other specialized approaches are utilized by a range of end-users, including hospitals, clinics, and other medical facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The neurofibromatosis treatment market research report is one of a series of new reports from The Business Research Company that provides neurofibromatosis treatment market statistics, including neurofibromatosis treatment industry global market size, regional shares, competitors with a neurofibromatosis treatment market share, detailed neurofibromatosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurofibromatosis treatment industry. This neurofibromatosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $13.09 billion in 2024 to $14.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to aging population, advancements in ophthalmology, patient-centered care, global healthcare access.
The neurofibromatosis treatment market size is expected to see rapid growth in the next few years. It will grow to $24.25 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include vision rehabilitation services, collaborative care models, data analytics and ai, optic nerve prostheses and implants.
The forecast of 13.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. rare disease care by increasing costs for Mitogen-activated protein kinase kinase(MEK) inhibitor therapies and tumor suppressor gene medications imported from Switzerland and the UK, potentially compromising tumor management and raising specialty pharmacy costs for Neurofibromatosis(NF) patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing healthcare expenditure is expected to drive the expansion of the neurofibromatosis treatment market. Healthcare expenditure includes all costs related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. It plays a vital role in advancing neurofibromatosis treatment, which involves various medical procedures such as surgeries, biopsies, and imaging tests like MRI and CT scans. Additionally, healthcare spending supports services like general medical care and neurofibromatosis treatment. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, compared to a modest 0.9% growth in 2022. Thus, the rise in healthcare expenditure is fueling the growth of the neurofibromatosis treatment market.
The growing focus on research and development (R&D) is expected to accelerate the growth of the neurofibromatosis treatment market. R&D activities refer to the increasing efforts by organizations to invest in systematic studies and innovative projects aimed at creating new products, technologies, or processes. The surge in R&D activities is driven by the need for innovation to maintain competitive edge, address consumer demands, and adapt to technological changes. The emphasis on developing treatments for neurofibromatosis has led to a rise in R&D efforts, with companies focusing on understanding the disease's underlying mechanisms and exploring new treatment options. For instance, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a European trade group representing the pharmaceutical industry, reported that pharmaceutical R&D expenditure in Europe reached $49.5 billion (€44.5 billion) in 2022, marking a 6.45% increase from $46.5 billion (€42.5 billion) in 2021. Therefore, the growing emphasis on R&D is driving the expansion of the neurofibromatosis treatment market.
Leading companies in the neurofibromatosis treatment market are advancing the development of innovative drugs and investigational targeted therapies, such as MEK inhibitors, to maintain their competitive edge. MEK inhibitors are a class of targeted therapies that block the MEK enzyme, which is part of the MAPK signaling pathway. This inhibition helps treat cancers and genetic disorders like neurofibromatosis by preventing cell growth and tumor progression. For example, in March 2024, SpringWorks Therapeutics, Inc., a US-based biopharmaceutical company, completed its submission of a new drug application (NDA) to the FDA for Mirdametinib, a treatment aimed at both children and adults with NF1-PN. Mirdametinib is a selective MEK inhibitor designed to target specific pathways responsible for the growth of neurofibromas. The FDA will review the safety and efficacy of this treatment, which could significantly improve the outcomes for individuals suffering from NF1-PN.
In October 2022, Pasithea Therapeutics, a prominent biotechnology company based in the US, completed the acquisition of AlloMek Therapeutics for $1.05 million. This strategic move is set to significantly enhance Pasithea Therapeutics' drug development efforts, with a specific focus on the Central Nervous System (CNS). AlloMek Therapeutics, a pharmaceutical company also based in the US, specializes in the development of treatments for a range of conditions including neurofibromatosis, congenital muscular disease, and catastrophic cardiomyopathy.
Major companies operating in the neurofibromatosis treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Vertex Pharmaceuticals Inc., Dr. Reddy's Laboratories, BioMarin Pharmaceutical, Allergan, BeiGene Ltd., BioXcel Therapeutics Inc., Blueprint Medicines Corp., Genway BioTech, SpringWorks Therapeutics, LGM Pharma LLC, Biotechnica Pharma Global, Affymax Inc.
North America was the largest region in the neurofibromatosis treatment market in 2024. The regions covered in neurofibromatosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the neurofibromatosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neurofibromatosis treatment market consists of revenues earned by entities by providing services such as stereotactic radiosurgery, genetic evaluation, physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis treatment market also includes sales of drugs such as selumetinib, bevacizumab and tricyclic antidepressants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neurofibromatosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neurofibromatosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neurofibromatosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurofibromatosis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Neurofibromatosis Treatment Market Trends And Strategies
4. Neurofibromatosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Neurofibromatosis Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Neurofibromatosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurofibromatosis Treatment Market Growth Rate Analysis
5.4. Global Neurofibromatosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurofibromatosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurofibromatosis Treatment Total Addressable Market (TAM)
6.1. Global Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neurofibromatosis 1 (NF1)
Neurofibromatosis 2 (NF2)
Schwannomatosis
6.2. Global Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Surgery
Radiation Therapy
Other Treatments
6.3. Global Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users
6.4. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Neurofibromatosis 1 (NF1), By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgical Interventions
Medication for Symptom Management
Genetic Counseling
6.5. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Neurofibromatosis 2 (NF2), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgical Interventions
Radiation Therapy
Medication for Symptom Management
6.6. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Schwannomatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgical Interventions
Pain Management Therapies
Genetic Counseling
7. Neurofibromatosis Treatment Market Regional And Country Analysis
7.1. Global Neurofibromatosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurofibromatosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
